Active Clinical Research for Blood Cancers

Comprehensive Cancer Centers of Nevada runs Phase II and Phase III research trials for blood cancers, leukemia and Hodgkins and Non-Hodgkins lymphoma cancers:

Hematalogic

Title:Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) **ENROLLMENT TO CLOSE 1/31/2018; COMPLETE ALL SCREENING BY 1/25/2018**
Study #: 15026 Phase: II/III
Contact Us: For information about this study, Email Us, or use our form field

Leukemia

Title: An open-label extension study in patients 65 years or older with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who participated in study PCYC-1115-CA (PCI-32765 versus chlorambucil)
Study #: i2071 Phase: III
Contact Us: For information about this study, Email Us, or use our form field

Title: An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study #: i2485 Phase: II/III
Contact Us: For information about this study, Email Us, or use our form field

Lymphomas

Title: An Open-Label Phase 2 Safety and Efficacy Study of INCB039110 in Combination with Ibrutinib in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Study #: i2272 Phase: II
Contact Us: For information about this study, Email Us, or use our form field.

Title: A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
Study#: i2471 Phase: II
Contact Us: For information about this study, Email Us, or use our form field.

Title: An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma
Study#: i2484 Phase: II/III
Contact Us: For information about this study, Email Us, or use our form field.

Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma – PCYC-1141-CA
Study#: 16176 Phase: III
Contact Us: For information about this study, Email Us, or use our form field.

Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma – PCYC-1141-CA
Study#: 16176 Phase: III
Contact Us: For information about this study, Email Us, or use our form field.

Multiple Myeloma

Title: A Phase 4, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Newly Diagnosed Multiple Myeloma Switching from a Bortezomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)
Study #: 17081 Phase: IV
Contact Us: For information about this study, Email Us, or use our form field.

There currently are no active Phase II or III research trials for these blood cancers:
Follicular Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Burkitt Lymphoma
Lymphoblastic Lymphoma
AIDS-Related B-Cell Lymphoma
Primary Cutaneous B-Cell Lymphoma
Peripheral T-Cell Lymphoma
Mycosis Fungoides/Sézary Syndrome
Adult T-Cell Leukemia/Lymphoma
Extranodal NK/T- Cell Lymphoma, nasal type
Post-Transplant Lymphoproliferative Disorders
T-Cell Prolymphocytic Leukemia
Hairy Cell Leukemia
Multiple Myeloma
Click here to Email Us, or use our form field for updates on research efforts.